Cartesian Therapeutics on Tuesday said an experimental cell therapy it's developing succeeded in a mid-stage clinical trial of people with the rare autoimmune condition myasthenia gravis, but shares ...
DUBLIN, Dec. 24, 2019 /PRNewswire/ -- The "Cartesian Robots - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering. The Global Cartesian Robots is accounted ...
FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune ...
GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC), (“the Company”) a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune ...
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...
Hosted on MSN
Cartesian shares updated Phase IIb Descartes-08 data and announces Phase III trial plans
Cartesian Therapeutics has announced updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate for generalised myasthenia gravis (MG), Descartes-08. The results ...
Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC), (“the Company ...
The Company will host a conference call and webcast to discuss the updated data, as well as details regarding the design of its planned Phase 3 trial, on Tuesday, December 3, 2024, at 7:30 a.m. ET.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback